Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-02-11
2008-12-23
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S375000, C435S377000, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07468356
ABSTRACT:
The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6710163 (2004-03-01), Buchardt et al.
patent: 2004/0171149 (2004-09-01), Wraight et al.
patent: WO-94/22486 (1994-10-01), None
patent: WO-9610401 (1996-04-01), None
patent: WO-98/22579 (1998-05-01), None
patent: WO-99/23259 (1999-05-01), None
patent: WO-0206345 (2002-01-01), None
patent: WO-02/24717 (2002-03-01), None
patent: WO-02/86105 (2002-10-01), None
Shapiro D, N. et al. (May 20, 1992). “Antisense-Mediated Reduction in Insulin like Growth Factor-I Receptor Expression Suppresses the Malignant Phenotype of a Human Rhabdomyosarcoma,” Proceedings of the Annual Meeting of the American Associate for Cancer Research, New York, NY, USA 33:354.
Wallenfiedman, M.A. et al. (Apr. 20, 1996). “Effects of IGF-1R Antisense and Nonsense Oligonucleotide Administration on 9L Glioblastoma and MAT B3 Breast Cancer Tumor Growth in Fischer 344 Rats,” Proceedings of the 87th Annual Meeting of Research, Apr. 20-24, 1996, Proceedings of the Annual Meeting of the American Association For Cancer Research, Philadelphia, AACR, USA 37:354.
Fogarty, R.D. et al. (Dec. 2002). “Sequence Dependence of C5-Propynyl-dU, dC-Phosphorothioate Oligonucleotide Inhibition of the Human IGF-I receptor: mRNA, Protein, and Cell Growth,” Antisense and Nucleic Acid Drug Development, 12(6):369-377.
White, P. et al. (Jun. 2006). “C-5 Propyne-Modified Oligonucleotides Penetrate the Epidermis in Psoriatic and not Normal Human Skin after Topical Application,” The Journal of Investigative Dermatology 118(6):1003-1007.
Database EMBL Online (Jul. 23, 1991). “Human Insulin-like Growth Factor I Receptor Gene, Promoter Region and 5′ end,” retrieved from EBI accession No. EM—PRO:M69229, database accession No. M69229.
Database EMBL Online (May 28, 2002). “CM0-GN0162-121000-624-b04—1 GN0162 Homo sapiens cDNA, mRNA sequence,” retrieved from EBI accession No. EM—EST: BQ366237, database accession No. BQ366237.
Supplementary Partial European Search Report mailed on Dec. 12, 2006 for PCT Application No. 04709958 filed on Nov. 2, 2004, 8 pages.
Bohula, E. A. et al. (May 2, 2003). “The Efficacy of Small Interfering RNAs Targeted to the Type 1 Insulin-Like Growth Factor Receptor (IGF1R) is Influenced by Secondary Structure in the IGF1R Transcript,”The Journal of Biological Chemistry278(18): 15991-15997.
International Search Report mailed Apr. 29, 2004, for PCT Application PCT/AU2004/00160 filed Feb. 11, 2004, 7 pages.
Pietrzkowski, Z. et al. (Sep. 1992). “Roles of Insulinlike Growth Factor 1 (IGF-1) and the IGF-1 Receptor in Epidermal Growth Factor-Stimulated Growth of 3T3 Cells,”Molecular and Cellular Biology12(9):3883-3889.
Porcu, P. et al. (Nov. 1992). “The Growth-Stimulatory Effect of Simian Virus 40 T Antigen Requires the Interaction of Insulinlike Growth Factor 1 with its Receptor,”Molecular and Cellular Biology12(11):5069-5077.
Resnicoff, M. et al. (Apr. 15, 1994). “Rat Glioblastoma Cells Expressing an Antisense RNA to the Insulin-Like Growth Factor-1 (IGF-1) Receptor are Nontumorigenic and Induce Regression of Wild-Type Tumors,”Cancer Research54:2218-2222.
U.S. Appl. No. 12/187,362, filed Aug. 6, 2008 for Wraight et al.
White, P. J. et al. (Jun. 2000). “Antisense Inhibition of IGF Receptor Expression in HaCaT Keratinocytes: A Model for Antisense Strategies in Keratinocytes,”Antisense&Nucleic Acid Drug Development10(3):195-203.
Wraight, C. J. et al. (May 2000). “Reversal of Epidermal Hyperproliferation in Psoriasis by Insulin-Like Growth Factor I Receptor Antisense Oligonucleotides,”Nature Biotechnology18:521-526.
Dean Nicholas M.
Dobie Kenneth W.
Werther George Arthur
Wraight Cristopher John
Antisense Therapeutics Ltd.
McGarry Sean R
Morrison & Foerster / LLP
LandOfFree
Modulation of insulin like growth factor I receptor expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of insulin like growth factor I receptor expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of insulin like growth factor I receptor expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4033539